240 related articles for article (PubMed ID: 30221819)
1. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
Gkini MA; Bewley AP
Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
[No Abstract] [Full Text] [Related]
2. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab.
Nakahara T; Konishi S; Yasukochi Y; Esaki H; Tsuji G; Kido-Nakahara M; Furue M
J Dermatol; 2019 May; 46(5):e157-e158. PubMed ID: 30353917
[No Abstract] [Full Text] [Related]
3. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'.
Martora F; Fabbrocini G; Marasca C; Battista T; Megna M
Clin Exp Dermatol; 2023 Jun; 48(6):701-703. PubMed ID: 36883596
[No Abstract] [Full Text] [Related]
5. Reply to 'Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab"'.
López Sanz P; Guzmán Pérez M; Guerrero Ramírez C; Manso Córdoba S; Alfaro Martínez ME; Azaña Defez JM
Clin Exp Dermatol; 2023 Jul; 48(8):940-941. PubMed ID: 37098182
[No Abstract] [Full Text] [Related]
6. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
7. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.
Gkalpakiotis S; Arenberger P; Fridman M; Arenbergerova M
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28730674
[No Abstract] [Full Text] [Related]
8. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum.
Blok JL; Li K; Brodmerkel C; Horvátovich P; Jonkman MF; Horváth B
Br J Dermatol; 2016 Apr; 174(4):839-46. PubMed ID: 26641739
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab-induced paradoxical hidradenitis suppurativa.
Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa.
Romaní J; Vilarrasa E; Martorell A; Fuertes I; Ciudad C; Molina-Leyva A
Dermatology; 2020; 236(1):21-24. PubMed ID: 31288233
[TBL] [Abstract][Full Text] [Related]
12. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
[TBL] [Abstract][Full Text] [Related]
13. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
Suh HY; Ahn JY; Park MY; Youn JI
J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
[No Abstract] [Full Text] [Related]
14. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
[No Abstract] [Full Text] [Related]
15. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction.
Sánchez-Martínez EM; García-Ruiz R; Moneva-Léniz LM; Mateu-Puchades A
Dermatol Ther; 2020 Nov; 33(6):e14054. PubMed ID: 32700796
[No Abstract] [Full Text] [Related]
16. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.
Watson N; Wu K; Farr P; Reynolds NJ; Hampton PJ
Br J Dermatol; 2019 Jan; 180(1):195-196. PubMed ID: 30101563
[No Abstract] [Full Text] [Related]
17. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
Cline A; Pichardo RO
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
[TBL] [Abstract][Full Text] [Related]
18. High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa.
Scholl L; Hessam S; Garcovich S; Bechara FG
Eur J Dermatol; 2019 Dec; 29(6):659-661. PubMed ID: 31903963
[No Abstract] [Full Text] [Related]
19. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
20. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
